Aditxt acquires Ignite Proteomics for $36M in preferred stock; issues $3.2M notes

Aditxt, Inc.

Acquired 100% of Ignite Proteomics for 36,000 Series A-2 Convertible Preferred Shares (stated value $36M).
Ignite's RPPA platform measures protein expression for therapy selection; CLIA lab, Medicare PLA ~$2,200/test.
Closed $3.2M note purchase (10% OID) with $2.875M funding; 6% interest, 9-month maturity, prepayable.
Company believes it regained compliance with Nasdaq minimum stockholders' equity requirement ($2.5M) after acquisition.
Ignite plans to launch program in 2026 targeting >600,000 US metastatic cancer patients.

item 1.01item 5.03item 2.01item 2.03item 3.02item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.